Research programme: multi-targeted cancer therapeutics - Curis

Drug Profile

Research programme: multi-targeted cancer therapeutics - Curis

Alternative Names: CU-0201; CU-201; CU-903; CU-906

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Curis
  • Class Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; Apoptosis stimulants; Bcr-abl tyrosine kinase inhibitors; Cyclin-dependent kinase inhibitors; Histone deacetylase inhibitors; Mitogen-activated protein kinase inhibitors; MTOR protein inhibitors; Src-Family kinase inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (PO)
  • 18 Oct 2012 Curis files an IND application with the US FDA for refractory lymphomas and multiple myeloma
  • 04 Apr 2012 Pharmacodynamics data from preclinical studies in Cancer presented at the 103rd Annual Meeting of the American Association for Cancer Research (AACR-2012)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top